Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP) (GALOP)

October 1, 2026 updated by: Assistance Publique - Hôpitaux de Paris

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Transient hyperglycemia of premature newborns results from an overall decrease in insulin sensitivity, which is responsible at the beta cell level for abnormalities of intragranular cleavage of proinsulin into insulin, leading to reduced active insulin secretion. Intravenous administration of exogenous insulin can be used to combat insulin resistance and lower blood glucose, but it is difficult to manage in premature newborns and is associated with a substantial risk of hypoglycemia. Glibenclamide, which stimulates endogenous insulin secretion and can be administered orally, might be an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75015
        • Hopital Necker - Enfants malades

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 7 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Newborn less than 34 week of amenorrhea corrected age
  • Birth weight < 1500 g
  • Birth term < 32 week of amenorrhea
  • Hyperglycemia ≥ 10 mmol/l in 2 measurements, 3 hours apart after potential reduction of glucose intakes following each department's protocol
  • Secure venous access point (umbilical venous catheter or epicutaneo-cava catheter)
  • Enteral feeding considered before inclusion or already established
  • Consent obtained from persons holding parental authority
  • Beneficiary of social security

Exclusion Criteria

  • Contraindication to enteral feeding (at the discretion of the clinician responsible for the child)
  • Contraindication to glibenclamide according to current SPC
  • Foetal growth restriction (FGR) birth weight < 3rd percentile (AUDIPOG definition)
  • Severe birth defect, including cardiac malformation associated with a risk of myocardial ischemia
  • Severe sepsis requiring mechanical ventilation or haemodynamic support
  • Severe renal dysfunction (serum creatinine > 120 µmol/l)
  • Severe hepatocellular failure (V factor less than the standard laboratory range for the age) and/or severe cholestasis (> 50 µmol/L)
  • Hyperglycemia associated with an error in administering glucose infusion
  • Profound hypophosphoremia (< 1 mmol/l)
  • Hypersensitivity to glibenclamide or other sulphonylureas or sulphonamides, or one of the excipients
  • Patient with continuous insulin IV administration
  • Patient treated with miconazole

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Glibenclamide oral

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

Amglidia®: glibenclamide oral suspension 6 mg/ml administered by gastric tube after dilution to 1/6th in human milk

  • For the first 10 patients during the test phase, four 0.2 ml samples will be taken at H3, H6, H10, and H24 (+/- 1 hour) after the first dose; an additional sample will be taken for patients whose blood sugar levels stabilize beyond 24 hours, after 6 hours of stable blood sugar levels (4-10 mmol/l);
  • For subsequent patients included during phase II:
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment.
  • 1 sample of 0.2 ml within the first 24 hours of treatment, during a care assessment
  • 1 sample of 0.2 ml per day at each daily check-up as part of care during the treatment period.
  • In centers that are unable to perform the samples and the appropriate techniques for centralizing these PK points, these samples will not be taken.

PK parameters of glibenclamide will be determined using nonlinear analysis: area under the plasma concentration time curve (AUC), absorption constant, apparent clearance and volume of distribution.

blood sampling at before first administration and after 24 hours for measurement of C-peptide proinsulin ratio if it is impossible to collect both volumes, the C-peptide collection will be prioritized

If there are not performed as part of standard care, biological monitoring of ALT, AST, complete blood count, hemostasis, urea, creatinine, blood ionogram, total bilirubin and conjugated bilirubin will be done before first administration at the following time frame : 48 hours after the first administration than each days during treatment period, and 48 hours after the end of treatment.

Transaminases and hemostasis will be done only in case of clinical indication before the first administration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood glucose control
Time Frame: At 72 hours after the first administration

The primary evaluation criteria is 72 hours blood glucose control on glibenclamide treatment (success of the treatment). This is defined as the non-use of insulin and absence of severe hypoglycemia (< 1.5 mmol/l) or persistent moderate hypoglycemia (< 2.6 mmol/l in 2 successive measurements (dextro) at an interval of more than 3 hours)

At 72 hours after the first administration

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall success of the treatment
Time Frame: At 36 week of amenorrhea corrected age

Overall success of the treatment defined by continuation to the end of treatment without recourse to insulin.

At 36 week of amenorrhea corrected age
Blood glucose profile on glibenclamide
Time Frame: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 10 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Time Frame: At the end of treatment assessed up to 15 days

Time between the start of glibenclamide treatment and the 1st blood glucose < 8 mmol/l

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Time Frame: At the end of treatment assessed up to 15 days

Proportion of time spent within the target blood glucose range (≥ 4 and < 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Time Frame: At the end of treatment assessed up to 15 days

Proportion of time spent above the target level (≥ 10 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Blood glucose profile on glibenclamide
Time Frame: At the end of treatment assessed up to 15 days

Proportion of time spent in hypoglycemia (< 2.6 mmol/l) during the period of glibenclamide treatment

At the end of treatment assessed up to 15 days
Duration of glibenclamide treatment
Time Frame: At the end of treatment assessed up to 15 days

Duration of glibenclamide treatment.

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Time Frame: At the end of treatment assessed up to 15 days

Carbohydrate

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Time Frame: At the end of treatment assessed up to 15 days

lipid

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Time Frame: At the end of treatment assessed up to 15 days

protein

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Time Frame: At the end of treatment assessed up to 15 days

mean caloric intake (kcal/kg/day) during treatment

At the end of treatment assessed up to 15 days
Nutritional intakes and growth:
Time Frame: At the end of treatment assessed up to 15 days

mean weight gain (g/kg/day)

At the end of treatment assessed up to 15 days
Nutritional intakes and growth
Time Frame: At 36 week of amenorrhea corrected age

Carbohydrate

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Time Frame: At 36 week of amenorrhea corrected age

lipid

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Time Frame: At 36 week of amenorrhea corrected age

protein

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Time Frame: At 36 week of amenorrhea corrected age

mean caloric intake (kcal/kg/day) during treatment

At 36 week of amenorrhea corrected age
Nutritional intakes and growth:
Time Frame: At 36 week of amenorrhea corrected age

mean weight gain ((g/kg/day)

At 36 week of amenorrhea corrected age
Number of children with episode of hypoglycemia
Time Frame: At 72 hours after first administration

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At 72 hours after first administration
Number of children with episode of hypoglycemia
Time Frame: At the end of treatment assessed up to 15 days

Number of children with at least one episode of moderate (blood glucose < 2.6 mmol/l) or severe (< 1.5 mmol/l) hypoglycemia

At the end of treatment assessed up to 15 days
Type of adverse reactions on glibenclamide
Time Frame: At 36 week of amenorrhea corrected age

evaluation of the type of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of adverse reactions on glibenclamide
Time Frame: At 36 week of amenorrhea corrected age

evaluation of number of adverse reactions identified during the study

At 36 week of amenorrhea corrected age
Number of participants with co-morbidity
Time Frame: At 36 week of amenorrhea corrected age

Neonatal morbidity assessed at 36 WA corrected age: intraventricular haemorrhage, periventricular leukomalacia, retinopathy of premature newborns, haemodynamic disorders, ulcerative necrotising enterocolitis

At 36 week of amenorrhea corrected age
Mortality
Time Frame: At 36 week of amenorrhea corrected age

Mortality will be assessed

At 36 week of amenorrhea corrected age
Dose adjustment
Time Frame: At the end of treatment assessed up to 15 days

Number of dose adjustments, to evaluate the easy of use

At the end of treatment assessed up to 15 days
ease of use by caregivers
Time Frame: At day one of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day one of treatment
ease of use by caregivers
Time Frame: At day two of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day two of treatment
ease of use by caregivers
Time Frame: At day three of treatment

Assessment scores by visual-analogue scale for ease of use by caregivers; 0 as the lowest score, 10 as the highest score

At day three of treatment
Plasma concentrations of glibenclamide
Time Frame: At 3 hours after the first administration

Evaluated by the pharmacokinetics study

At 3 hours after the first administration
Plasma concentrations of glibenclamide
Time Frame: At 6 hours after the first administration

Evaluated by the pharmacokinetics study

At 6 hours after the first administration
Plasma concentrations of glibenclamide
Time Frame: At 10 hours after the first administration

Evaluated by the pharmacokinetics study

At 10 hours after the first administration
Plasma concentrations of glibenclamide
Time Frame: At 24 hours after the first administration

Evaluated by the pharmacokinetics study

At 24 hours after the first administration
Plasma concentrations of glibenclamide
Time Frame: At 24 hours of blood glucose stabilization

Evaluated by the pharmacokinetics study

At 24 hours of blood glucose stabilization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Jacques BELTRAND, Pr, Assistance Publique - Hôpitaux de Paris
  • Study Director: Michel POLAK, Assistance Publique - Hôpitaux de Paris
  • Study Director: Delphine MITANCHEZ, CHRU de Tours

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 20, 2023

Primary Completion (Actual)

October 30, 2025

Study Completion (Actual)

January 8, 2026

Study Registration Dates

First Submitted

December 7, 2022

First Submitted That Met QC Criteria

January 6, 2023

First Posted (Actual)

January 18, 2023

Study Record Updates

Last Update Posted (Actual)

October 2, 2026

Last Update Submitted That Met QC Criteria

October 1, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • P160916J
  • 2021-005766-18 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.